Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
GemVax & KAEL Says Top Shareholder Extends Share Pledge to Dec. 15

GemVax & KAEL Says Top Shareholder Extends Share Pledge to Dec. 15

BitgetBitget2026/11/02 07:56
  • GemVax & KAEL issued a correction Nov. 2, 2026, extending its largest shareholder’s share-backed borrowing agreement to Dec. 15 from Oct. 31.
  • The renewed agreement covers 300,000 shares pledged by Gem & Company, with collateral set at KRW 5 billion.
  • Total pledged shares stand at 5,429,489 across 11 contracts, securing borrowings of KRW 44.77 billion.
  • Full enforcement would reduce Gem & Company’s stake to 0.01% from 11.95%, potentially changing the largest shareholder.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GemVax & KAEL Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102900726), on November 02, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion

Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.

智通财经•2026/11/09 23:57